CAS 57568-80-6
:4-Morfolinacarboximidamide, N-cicloesil-N'-triciclo[3.3.1.13,7]dec-1-il-, cloridrato (1:1)
- 4-Morpholinecarboximidamide, N-cyclohexyl-N'-tricyclo[3.3.1.1~3,7~]dec-1-yl-, hydrochloride (1:1)
- 4-Morpholinecarboximidamide, N-cyclohexyl-N′-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl-, hydrochloride (1:1)
- 4-Morpholinecarboximidamide, N-cyclohexyl-N′-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl-, monohydrochloride
- N'-(Adamantan-1-yl)-N-cyclohexylmorpholine-4-carboximidamide hydrochloride (1:1)
- N-[1-Adamantyl]-N-cyclohexyl-4-morpholinecarboxamidine hydrochloride
- Pnu 37883A
- Pnu 37887A
- U 37883A
- 4-Morpholinecarboximidamide, N-cyclohexyl-N′-tricyclo[3.3.1.13,7]dec-1-yl-, monohydrochloride
- 4-Morpholinecarboximidamide, N-cyclohexyl-N′-tricyclo[3.3.1.13,7]dec-1-yl-, hydrochloride (1:1)
PNU 37883 hydrochloride
CAS:PNU 37883 hydrochloride is a potent inhibitor of the ATP-sensitive potassium channel that blocks the opening of the channel in response to changes in intracellular ATP levels. PNU 37883 hydrochloride blocks both the α and β subunits of these channels, which are necessary for transmitting signals from outside to inside cells. It has been shown to inhibit papillary muscle contractions and reduce blood pressure in vivo. PNU 37883 hydrochloride also inhibits renal glomerular filtration rate and cardiac contractility, as well as inhibiting atp-sensitive K+ channels in mesenteric artery. This drug has also been shown to be effective against hepatitis C virus infection, both in vitro and in vivo. As an additional mechanism, it has been shown to increase pluripotent cells such as embryonic stem cells or induced pluripotent stem cells by blocking cyclase activity.
Formula:C21H35N3O·HClPurezza:Min. 95%Peso molecolare:381.98 g/molPNU 37883 hydrochloride
CAS:Kir6 (KATP) channel antagonistFormula:C21H36ClN3OPurezza:98%Colore e forma:SolidPeso molecolare:381.98

